Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850310 | 0.88 | BACE1 (0.38) | BACE1GRIN1GRIN2BDGAT2CTSD | |
| SCHEMBL1855992 | 0.85 | BACE1 (0.38) | BACE1GRIN1GRIN2BDGAT2CTSD | |
| SCHEMBL1869646 | 0.84 | BACE1 (0.40) | BACE1GRIN1GRIN2BDGAT2CTSD | |
| SCHEMBL1951532 | 0.83 | BACE1 (0.37) | BACE1GRIN1GRIN2BDGAT2CTSD | |
| SCHEMBL1857520 | 0.79 | BACE1 (0.40) | BACE1GRIN1GRIN2BCTSDEPHX2 | |
| SCHEMBL1950237 | 0.78 | BACE1 (0.38) | BACE1GRIN1GRIN2BDGAT2CTSD | |
| SCHEMBL1950045 | 0.77 | BACE1 (0.39) | BACE1GRIN1GRIN2BEPHX2CACNA1B | |
| SCHEMBL2805368 | 0.77 | GRIN1 (0.34) | BACE1GRIN1GRIN2BCTSDCACNA1B | |
| SCHEMBL1951290 | 0.76 | BACE1 (0.42) | BACE1GRIN1GRIN2BDGAT2CTSD | |
| SCHEMBL1852732 | 0.76 | GRIN1 (0.34) | BACE1GRIN1GRIN2BCTSDCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136842-A1 | Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers | MERCK SHARP & DOHME CORP. | 2011-06-09 | — | — | US | disclosed |
| US-20110136842-A1 | Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers | MERCK SHARP & DOHME CORP. | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136842-A1 | Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers | CACNA1D, TRPV1, CACNA1S | BACE1 196/4885GRIN1 195/4885GRIN2B 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.